title: [Effects 'of β3 adrenoceptors on the contractility of rat thoracic aorta smooth muscle and the mechanism].
abstract: OBJECTIVE
  To observe the effect of β₃adrenoceptors (β₃-AR) activation on rat thoracic aorta smooth muscle contractility and the possible related mechanism.
  
  
  METHODS
  The endothelium removed thoracic aorta was pre-contracted with 30 mmol/L KCl physiological saline solution (PSS). Then the tension of the thoracic aorta was recorded in presence of BRL37344 (BRL) to determine the action of β₃-AR. The tension of the thoracic aorta was also recorded in the presence of Propranolol (PRA), SR59230A (SR), L-NNA, H-89 and Iberiotoxin (IBTX) respectively to reveal the underling mechanism of β₃-AR activation on rat vascular smooth muscle. Immunohistochemistry was adopted to confirm the existence and the distribution of β₃-AR in rat thoracic aorta.
  
  
  RESULTS
  The results showed that: (1) The thoracic aorta was relaxed by β₃-AR activation, with a relaxation percentage of (10.59 ± 0.79). (2) β₃-AR was expressed in both endothelial and smooth muscle layer in thoracic aorta sections of rats. (3) PRA did not block the effect of BRL on the thoracic aorta. The relaxation actions of BRL could be antagonized by pre-incubating the thoracic aorta with SR. (4) L-NNA (a NOS inhibitor) and H-89 (a PKA inhibitor) reversed the relaxation effect of BRL on vascular smooth muscle. (5) The effect of BRL was decreased after application of Ibriotoxin (IBTX), a large conductance calcium dependent potassium channel blocker.
  
  
  CONCLUSIONS
  The results confirmed that activation of β₃-AR led to relaxation of thoracic aorta smooth muscle. The relaxation action of β₃-AR on smooth muscle of rat thoracic aorta was related to activation of NOS and PKA signaling pathway. Large conductance Ca²⁺-K⁺ channels were involved in the relaxation action of β₃-AR activation on rat thoracic aorta smooth muscle.
authors.forename: Xiao-peng
authors.initials: XP
authors.lastname: Li
authors.forename: Qian-qian
authors.initials: QQ
authors.lastname: Zhao
authors.forename: Lan
authors.initials: L
authors.lastname: Yang
authors.forename: Hai-qing
authors.initials: HQ
authors.lastname: Li
authors.forename: Xiang-li
authors.initials: XL
authors.lastname: Cui
mesh_terms: D000818:Animals; D001013:Aorta, Thoracic / Q000502:physiology*; D066298:In Vitro Techniques; D007546:Isoquinolines; D051036:Large-Conductance Calcium-Activated Potassium Channels / Q000502:physiology; D009119:Muscle Contraction; D009126:Muscle Relaxation; D009131:Muscle, Smooth, Vascular / Q000502:physiology*; D019335:Nitroarginine; D010455:Peptides; D011412:Propanolamines; D011433:Propranolol; D051381:Rats; D022702:Receptors, Adrenergic, beta-3 / Q000502:physiology*; D015398:Signal Transduction; D013449:Sulfonamides
chemical_list: C097869:3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate; D007546:Isoquinolines; D051036:Large-Conductance Calcium-Activated Potassium Channels; D010455:Peptides; D011412:Propanolamines; D022702:Receptors, Adrenergic, beta-3; D013449:Sulfonamides; D019335:Nitroarginine; C064719:iberiotoxin; D011433:Propranolol; C063509:N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide